A Natural Organic Compound “Decursin” Has Both Antitumor and Renal Protective Effects: Treatment for Osteosarcoma

Figure 6

Effects of decursin and/or cisplatin in vivo. The synergistic effect, as well as the effect of adding cisplatin to decursin, was evaluated using xenografted mice. Decursin and cisplatin were administered intraperitoneally every three days after the tumor volume reached 50 mm³. (a) Tumor volumes of mice were measured after administration of decursin and cisplatin (n = 5). (b) The mice on day 21. The tumor volume was presented for every four out of five animals. (c, d) The tumor weights were measured on day 21. (e) The dose of cisplatin was increased, and the tumor volume was measured after administration of decursin and cisplatin (n = 5). (f) Under conditions of increased cisplatin, tumor weight was measured on day 21. (g) Body weight of mice was evaluated in the decursin and/or cisplatin (2 mg/kg or 4 mg/kg) group. (h) Blood samples (n = 5) were collected for assessment of liver and renal toxicity associated with decursin and/or cisplatin administration. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cre, creatinine. (i, j) Renal weight was measured in sacrificed rats (n = 5). (k, l) The resected kidney was stained with hematoxylin-eosin and observed at high or low magnification (scale bar = (k) 20 μm; (l) 100 μm).  < 0.05 and  < 0.01. N.S.: not significant.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)